$2.81
0[0.00%]
Last update: 4:00PM Get Real Time Here
Arbutus Biopharma
(NASDAQ:ABUS)Latest News for Arbutus Biopharma Stock (NASDAQ:ABUS)
Arbutus Biopharma Stock (NASDAQ: ABUS)
Categories: All
Friday, May 03, 2024
Thursday, May 02, 2024
Thursday, April 04, 2024
- Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From JudgeVandana Singh - Apr 4, 2024, 2:32PM
- Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound AheadSurbhi Jain - Apr 4, 2024, 9:34AM
- JMP Securities Reiterates Market Outperform on Arbutus Biopharma, Maintains $4 Price TargetBenzinga Newsdesk - Apr 4, 2024, 8:49AM
- Arbutus Biopharma Announces Claim Construction Ruling In Ongoing Patent Infringement Lawsuit Against ModernaBenzinga Newsdesk - Apr 4, 2024, 8:42AM
Wednesday, April 03, 2024
- Arbutus Stock Soars 20% As It Heads To Trial With Moderna In Covid Vaccine Patent ClaimNeil Dennis - Apr 3, 2024, 3:37PM
- Arbutus Biopharma shares are trading higher amid circulation of documents from an Arbutus/Genevant vs Moderna patent infringement lawsuit.Benzinga Newsdesk - Apr 3, 2024, 12:57PM
- Watching Arbutus Biopharma; Traders Circulate Arbutus/Genevant Vs Moderna Patent Infringement Lawsuit Claim Construction Order Court DocumentsBenzinga Newsdesk - Apr 3, 2024, 12:22PM
Friday, March 01, 2024
Thursday, February 29, 2024
- Arbutus Biopharma's 2023 End Cash And Investments Of $132M Is Expected To Provide Cash Runway Into Q1 2026Benzinga Newsdesk - Feb 29, 2024, 7:40AM
- Arbutus Biopharma Q4 EPS $(0.12), Inline, Sales $2.15M Miss $4.79M EstimateBenzinga Newsdesk - Feb 29, 2024, 7:36AM
- Earnings Scheduled For February 29, 2024Benzinga Insights - Feb 29, 2024, 5:15AM
Thursday, February 08, 2024
Thursday, November 09, 2023
Tuesday, November 07, 2023
- Arbutus Biopharma Q3 2023 EPS $(0.12) Misses $(0.11) Estimate, Sales $4.658M Misses $4.752M EstimateBenzinga Newsdesk - Nov 7, 2023, 7:34AM
- Arbutus Says Announces Workforce Reduction Of 24% Effective Nov. 6, 2023, Primarily Affecting Research FunctionBenzinga Newsdesk - Nov 7, 2023, 7:32AM
- Arbutus CEO William Collier To Retire At The End Of 2023; Michael J. McElhaugh To Serve As Interim CEOBenzinga Newsdesk - Nov 7, 2023, 7:21AM
- Arbutus CEO William Collier To Retire Dec. 31, 2023Benzinga Newsdesk - Nov 7, 2023, 7:18AM
- Earnings Scheduled For November 7, 2023Benzinga Insights - Nov 7, 2023, 6:34AM
Thursday, October 05, 2023
Tuesday, September 12, 2023
Monday, September 11, 2023
Friday, August 04, 2023
Thursday, August 03, 2023
- Arbutus Biopharma Had Cash, Cash Equivalents And Investments In Marketable Securities Of $163.5M, With Cash Runway Into Q1 2025; 2023 Net Cash Burn To Range From Between $90M-$95MBenzinga Newsdesk - Aug 3, 2023, 7:36AM
- Arbutus Biopharma Q2 EPS $(0.10) Beats $(0.12) Estimate, Sales $4.65M Miss $5.02M EstimateBenzinga Newsdesk - Aug 3, 2023, 7:34AM
- Earnings Scheduled For August 3, 2023Benzinga Insights - Aug 3, 2023, 6:59AM
Tuesday, July 11, 2023
Thursday, July 06, 2023
Thursday, June 22, 2023
Wednesday, June 21, 2023
- Arbutus Biopharma Has Dosed The First Patient In The Additional Treatment Arm Of The AB-729 Phase 2a Triple Combination Clinical Trial That Has Been Expanded To Include A Pd-1 Monoclonal Antibody, Opdivo (Nivolumab)Benzinga Newsdesk - Jun 21, 2023, 7:33AM
- Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023Benzinga Newsdesk - Jun 21, 2023, 3:30AM
Friday, May 05, 2023
Thursday, May 04, 2023
- Arbutus Biopharma Q1 Exceeds Consensus View; Cuts Cash Burn GuidanceLekha Gupta - May 4, 2023, 3:33PM
- Recap: Arbutus Biopharma Q1 EarningsBenzinga Insights - May 4, 2023, 7:46AM
- Arbutus Biopharma Q1 EPS $(0.10) Beats $(0.14) Estimate, Sales $6.69M Beat $6.03M EstimateBenzinga Newsdesk - May 4, 2023, 7:36AM
- Earnings Scheduled For May 4, 2023Benzinga Insights - May 4, 2023, 6:34AM
Wednesday, May 03, 2023
Friday, April 28, 2023
Thursday, April 27, 2023
Tuesday, April 25, 2023
- Arbutus Biopharma shares are trading lower after the company reported the FDA issued a clinical hold on its IND Application for AB-101.Benzinga Newsdesk - Apr 25, 2023, 12:04PM
- Why Arbutus Biopharma Stock Is Plunging TodayVandana Singh - Apr 25, 2023, 9:57AM
- Arbutus Reports FDA Clinical Hold On IND Application For AB-101, An Oral PD-L1 InhibitorBenzinga Newsdesk - Apr 25, 2023, 7:32AM